[Multiple myeloma with IgH::MYC and multiple extramedullary lesions]

Rinsho Ketsueki. 2024;65(3):147-152. doi: 10.11406/rinketsu.65.147.
[Article in Japanese]

Abstract

A 41-year-old woman with right shoulder pain was found to have multiple tumors with osteolysis and M-proteinemia. Abnormal plasma cells (CD38+, CD138+, Igλ≫κ) were detected in 1.4% of bone marrow nucleated cells, and G-banding analysis revealed a 46,XX,t (8;14), (q24;q32) karyotype in 4 of 20 cells analyzed. A biopsy specimen from an extramedullary lesion had a packed proliferation of aberrant plasmacytoid cells with positive IgH::MYC fusion signals on fluorescence in situ hybridization. The patient was diagnosed with symptomatic multiple myeloma and treated with the BLd regimen, which significantly reduced M protein levels. Extramedullary lesions were initially reduced, but increased again after four cycles. The lesions disappeared with subsequent EPOCH chemotherapy and radiation, and complete remission was confirmed. The patient was then treated with high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Complete remission was maintained for over one year with lenalidomide maintenance therapy. A solitary IgH::MYC chromosomal translocation is extremely rare in multiple myeloma and may be associated with high tumor proliferative capacity, multiple extramedullary lesions, and poor prognosis. Combined therapeutic modalities with novel and conventional chemotherapy and radiation might be a promising treatment strategy for patients with this type of multiple myeloma.

Keywords: Extramedullary plasmacytoma; IgH::MYC; Multiple myeloma.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Female
  • Humans
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Lenalidomide / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / therapy
  • Translocation, Genetic

Substances

  • Lenalidomide